Additionally, TFAP2C directly interacts with the EGFR gene to promote its expression, resulting in luminal breast cancer cell proliferation and an improved therapeutic effect of TKIs (Vandetanib) [106, 126]. This evidence concerns the gene TFAP2C and breast cancer.